Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.

Khasraw M, Townsend A, Price T, Hart J, Bell D, Pavlakis N.

Intern Med J. 2010 Jun;40(6):453-8. doi: 10.1111/j.1445-5994.2010.02245.x.

PMID:
20636828
[PubMed - indexed for MEDLINE]
2.

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group.

J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24.

PMID:
19704057
[PubMed - indexed for MEDLINE]
Free Article
3.

Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.

Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF.

Ann Oncol. 2000 Sep;11(9):1127-30.

PMID:
11061606
[PubMed - indexed for MEDLINE]
Free Article
4.

The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.

Shi W, Buchanan KD, Johnston CF, Larkin C, Ong YL, Ferguson R, Laird J.

Clin Endocrinol (Oxf). 1998 Mar;48(3):303-9.

PMID:
9578820
[PubMed - indexed for MEDLINE]
5.

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.

Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, Schlumberger M, Rougier P.

Eur J Cancer. 2001 May;37(8):1014-9.

PMID:
11334727
[PubMed - indexed for MEDLINE]
6.

Cyto-reduction of neuroendocrine tumours using Sandostatin LAR in combination with Infergen: results of a case series.

Wang HS, Oh DS, Ohning GV, Pisegna JR.

J Pharm Pharmacol. 2006 Dec;58(12):1623-8.

PMID:
17331326
[PubMed - indexed for MEDLINE]
7.

Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.

Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME.

Aliment Pharmacol Ther. 2009 Oct;30(7):733-40. doi: 10.1111/j.1365-2036.2009.04083.x. Epub 2009 Jul 2.

PMID:
19573169
[PubMed - indexed for MEDLINE]
8.

Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.

Slaby O, Sachlova M, Bednarikova M, Fabian P, Svoboda M, Vytopilova S, Valik D, Vyzula R.

Cancer Biother Radiopharm. 2010 Apr;25(2):237-43. doi: 10.1089/cbr.2009.0708.

PMID:
20423238
[PubMed - indexed for MEDLINE]
9.

Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.

Anthony L, Vinik AI.

Pancreas. 2011 Oct;40(7):987-94. doi: 10.1097/MPA.0b013e31821f66b4.

PMID:
21697761
[PubMed - indexed for MEDLINE]
10.

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.

Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B; International Lanreotide and Interferon Alfa Study Group.

J Clin Oncol. 2003 Jul 15;21(14):2689-96.

PMID:
12860945
[PubMed - indexed for MEDLINE]
11.

Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?

Bajetta E, Catena L, Procopio G, Bichisao E, Ferrari L, Della Torre S, De Dosso S, Iacobelli S, Buzzoni R, Mariani L, Rosai J.

Ann Oncol. 2005 Aug;16(8):1374-80. Epub 2005 Jun 6.

PMID:
15939719
[PubMed - indexed for MEDLINE]
Free Article
12.

High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.

Chadha MK, Lombardo J, Mashtare T, Wilding GE, Litwin A, Raczyk C, Gibbs JF, Kuvshinoff B, Javle MM, Iyer RV.

Anticancer Res. 2009 Oct;29(10):4127-30.

PMID:
19846960
[PubMed - indexed for MEDLINE]
Free Article
13.

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group.

Lancet. 2011 Dec 10;378(9808):2005-12. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25.

PMID:
22119496
[PubMed - indexed for MEDLINE]
14.

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.

Kaltsas GA, Mukherjee JJ, Isidori A, Kola B, Plowman PN, Monson JP, Grossman AB, Besser GM.

Clin Endocrinol (Oxf). 2002 Aug;57(2):169-83. Review.

PMID:
12153595
[PubMed - indexed for MEDLINE]
15.

The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy.

Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L.

Ann Oncol. 2001;12 Suppl 2:S105-9. Review.

PMID:
11762334
[PubMed - indexed for MEDLINE]
16.

Long-term follow-up of two patients with metastatic neuroendocrine tumours treated with octreotide.

van de Loosdrecht AA, van Bodegraven AA, Sepers JM, Sindram JW.

Neth J Med. 1998 Sep;53(3):118-23.

PMID:
9803143
[PubMed - indexed for MEDLINE]
17.

Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.

Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C.

Clin Endocrinol (Oxf). 2002 Jan;56(1):65-71.

PMID:
11849248
[PubMed - indexed for MEDLINE]
18.

[Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].

Simonenko VB, Dulin PA, Makanin MA.

Klin Med (Mosk). 2006;84(4):4-8. Review. Russian.

PMID:
16755846
[PubMed - indexed for MEDLINE]
19.

[Efficacy of somatostatin analogs in the treatment of neuroendocrine tumours and paraneoplastic syndromes].

Sperlongano P, De Falco M, Pisaniello D, Parmeggiani D, Parmeggiani U.

Minerva Endocrinol. 2001 Dec;26(4):293-5. Italian.

PMID:
11782719
[PubMed - indexed for MEDLINE]
20.

Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.

Oberg K.

Ann Oncol. 2001;12 Suppl 2:S111-4. Review.

PMID:
11762335
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk